Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Nanoscope Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference | ||
| By: PR Newswire Association LLC. - 22 Nov 2022 | Back to overview list |
|
|
DALLAS, Nov. 22, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that management will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, in New York.
Chief Executive Officer, Sulagna Bhattacharya, and Chief Medical Officer, Aaron Osborne will provide a company update on Nanoscope's clinical and corporate activities on Thursday, December 1, at 2:10 PM Eastern Time in the Harlem Track of the Lotte New York Palace. Nanoscope leadership will be available for in-person meetings at the conference on Thursday, December 1. About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company's lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy. Investor Contact:
SOURCE Nanoscope Therapeutics 
|
||
|
||
 | Back to overview list | |
View original content to download multimedia: